From Lab to Vaccine Vial: The Historic Manufacturing Journey of Johnson & Johnson's Janssen COVID-19 Vaccine
As the U.S. government announces an agreement between Johnson & Johnson and Merck to collaborate on vaccine production, we trace all the steps it takes—from growing cells in a bioreactor to prepping palettes with high-tech track-and-trace technology—to develop and manufacture a vaccine during a pandemic.
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
Johnson & Johnson Innovation - JLABS Year in Review Spotlights Resilience of Global Ecosystem
Johnson & Johnson Innovation – JLABS Global Head Melinda Richter discusses how the JLABS ecosystem sought to meet the moment, emphasizing the work of JLABS companies aiming to find potential COVID-19 solutions, as well as the importance of fostering diversity and inclusion and addressing health inequities.